Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations

9 Feb 2006

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research
Share to Protein Tyrosine Phosphatases

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 16467864
DOI: 10.1038/sj.leu.2404136

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutationsPMID 16467864Read ↗

Loss of multiple point mutations of RAS genes associated with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome.Semantic proximity Read ↗

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.Semantic proximity Read ↗

In Response to: Pediatric Myelodysplastic Syndrome with Germline RRAS Mutation: Expanding the Phenotype of RASopathies.Semantic proximity Read ↗

Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.Semantic proximity Read ↗

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.Semantic proximity Read ↗

Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndromeSemantic proximity Read ↗

Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemiaSemantic proximity Read ↗

Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.Semantic proximity Read ↗

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high‐risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasiaSemantic proximity Read ↗

New mechanisms of AML1 gene alteration in hematological malignancies.Semantic proximity Read ↗

Alteration of N-ras mutation in a patient with AML M4 and trilineage myelodysplasia.Semantic proximity Read ↗

Prognostic impact of RAS-pathway mutations in patients with myelofibrosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.